WO2007027187A1 - Anti-inflammatory compositions and methods of use - Google Patents
Anti-inflammatory compositions and methods of use Download PDFInfo
- Publication number
- WO2007027187A1 WO2007027187A1 PCT/US2005/034398 US2005034398W WO2007027187A1 WO 2007027187 A1 WO2007027187 A1 WO 2007027187A1 US 2005034398 W US2005034398 W US 2005034398W WO 2007027187 A1 WO2007027187 A1 WO 2007027187A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- agent
- weight percent
- inflammatory
- personal care
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the present invention relates to compositions that tend to exhibit anti-inflammatory properties, and more particularly, to compositions comprising combinations of anti-inflammatory agents, which compositions tend to exhibit unexpectedly high, synergistic anti-inflammatory properties as compared to conventional compositions.
- a wide variety of skin care actives suitable for use in personal care compositions are known.
- skin care actives include olive leaf extract, which has been described as exhibiting antihypertensive and hypoglycemic activities, antiradical properties for alimentary and cosmetics, and anti-inflammatory activity when given via the oral route (see, for example, Leaf extract ofOlea europea rich in oleuropeine, products from it, their application as medicines and compositions containing them. Combes, Georges;. Escaut, Alexandre. Fr.
- Oil extracts a such as Boswellia Serrata oil extract (Frankincense), described as exhibiting anti-tumor and anti-arthritic properties, and oat oil extract, described as exhibiting anti-irritant and an antioxidant properties.
- Oil extracts a such as Boswellia Serrata oil extract (Frankincense), described as exhibiting anti-tumor and anti-arthritic properties
- oat oil extract described as exhibiting anti-irritant and an antioxidant properties.
- Applicants have recognized the need to develop combinations of skin care actives to effectively treat, reduce, and/or prevent inflammation of the skin due to any of a variety of sources. While applicants have recognized a variety of actives that tend to exhibit antiinflammatory properties, it is generally difficult, if not impossible, to predict combinations of such actives that will exhibit unexpectedly high, synergistic anti-inflammatory properties and effectiveness at reducing inflammation.
- compositions that meet the outstanding need for combinations of skin care actives that exhibit unexpectedly high, synergistic anti-inflammatory properties.
- applicants have recognized that certain of such compositions exhibit surprisingly high anti-inflammatory properties in relatively low amounts.
- compositions comprising (a) an anti-inflammatory agent selected from the group consisting of olive leaf extracts, holly herb, sappan wood, feverfew, and combinations of two or more thereof, and (b) an anti-inflammatory agent comprising at least one lipoaminoacid and at least one metal salt.
- the present invention provides personal care products comprising a composition of the present invention.
- the present invention provides methods of treating/reducing inflammation and/or redness by contacting skin in need of inflammation reduction with a composition of the present invention and/or contacting skin in need of inflammation reduction with a personal care product of the present invention.
- the present invention provides compositions comprising (a) an anti-inflammatory agent comprising olive leaf extract, holly herb, sappan wood, feverfew, or combinations of two or more thereof, and (b) an anti-inflammatory agent comprising at least one lipoaminoacid or salt thereof and at least one metal salt.
- an anti-inflammatory agent comprising olive leaf extract, holly herb, sappan wood, feverfew, or combinations of two or more thereof
- an anti-inflammatory agent comprising at least one lipoaminoacid or salt thereof and at least one metal salt.
- anti-inflammatory agent refers generally to any compound or combination of compounds that, upon introduction to skin which exhibits inflammation, tends to reduce such inflammation.
- actives suitable for use in the present invention include olive leaf extracts, including any water or oil-soluble extracts of Olea europea, as well as, holly herb, sappan wood, feverfew, combinations of two or more thereof, and the like.
- the active comprises olive leaf extract.
- Suitable actives are commercially available from one or more sources, for example, olive leaf extract (water- soluble extract available from B&T srl (Milano, Italy) under the trade name Eurol BT and oil- soluble extract available from Active Organics), holy herb (available from Sederma Edison NJ), and feverfew (available from Indena, Milan Italy), and the like.
- olive leaf extract water- soluble extract available from B&T srl (Milano, Italy) under the trade name Eurol BT and oil- soluble extract available from Active Organics
- holy herb available from Sederma Edison NJ
- feverfew available from Indena, Milan Italy
- any suitable, cosmetically-acceptable anti-inflammatory agent comprising at least one lipoamino acid and at least one metal salt may be used herein.
- suitable lipoamino acids include those produced by linking amino acids, such as alanine, glycine, glutamic acid, aspartic acid, and the like, to fatty acid chains, such as, for example, cocoyl or other chains, and salts derived therefrom.
- Certain preferred lipoamino acids include cocoyl aminoacids (formed by linking alanine, glycine, glutamic acid, and aspartic acid to cocoyl moieties), and salts thereof, including sodium salts, potassium salts, and the like.
- Certain particularly preferred lipoamino acids comprise sodium cocoyl aminoacids.
- suitable metal salts include sodium, potassium, calcium, magnesium salts, combinations of two or more and the like.
- Certain preferred metal salts include aspartates, gluconates, glycophosphates, and the like.
- Certain preferred anti-inflammatory agents comprise at least one lipoamino acid and at least one metal aspartate.
- Certain more preferred agents comprises one or more lipoamino acids and at least two metal aspartates.
- a particularly preferred anti-inflammatory agent comprises a combination of sodium cocoyl aminoacids, magnesium aspartate, and potassium aspartate (in combination with sarcosine) available commercially from Seppic under the trade names Sepicalm S and Sepicalm S WP.
- any suitable amounts of (a) anti-inflammatory agent selected from the group consisting of olive leaf extract, holly herb, sappan wood, feverfew, and combinations of two or more thereof (“agent (a)”) and (b) anti-inflammatory agent comprising at least one lipoamino acid and at least one metal salt (“agent(b)”) may be used in the present invention.
- the present compositions comprise from greater than zero to less than 100 weight percent of agent (a) and from less than 100 to greater than zero weight percent of agent (b) (as used herein and throughout, the term "weight percent” means the percent by weight, on an active basis, of an agent based on the total active weight of agent (a) and agent (b) unless specifically described otherwise).
- compositions comprise from about 10 to about 90 weight percent of agent (a) and from about 90 to about 10 weight percent of agent (b), more preferably from about 20 to about 80 weight percent of agent (a) and from about 80 to about 20 weight percent of agent (b), and even more preferably from about 40 to about 60 weight percent of agent (a) and from about 60 to about 40 weight percent of agent (b).
- the weight ratio of agent (a) to agent (b) is from about 4: 1 to about 1 :4. In certain other preferred embodiments, the ratio is from about 2: 1 to about 1 :2, and in other embodiments preferably about 1:1.
- compositions of the present invention may further include any of a variety of additional anti-inflammatory and other cosmetically-active agents in addition to agent (a) and agent (b).
- a "cosmetically active agent” is a compound that has a cosmetic or therapeutic effect on the skin, e.g., agents to treat wrinkles, acne, or to lighten the skin.
- the agent is selected from, but not limited to, the group consisting of: hydroxy acids; benzoyl peroxide; sulfur resorcinol; D-panthenol; hydroquinone; anti-inflammatory agents; skin lightening agents; antimicrobial and antifungal agents such a miconazole, ketoconazole, and elubial; vitamins such as ascorbic acid; tocopherols and tocotrienols such as tocopheryl acetate; retinoids such retinol, retinal, retinyl palmitate, retinyl acetate, and retinoic acid; hormones such as estrogens and dihydroxyandrostene dione; 2-dimethylaminoethanol; lipoic acid; amino acids such a proline and tyrosine; lactobionic acid; self-tanning agents such as dihydroxy acetone; dimethyl aminoethanol; acetyl-coenzyme A; niacin; riboflavin;
- hydroxy acids include, but are not limited, to (i) alpha-hydroxy acids such as glycolic acid, lactic acid, malic acid, citric acid, and tartaric acid, (ii) beta-hydroxy acids such as salicylic acid, and/or (iii) polyhydroxy acids. See, e.g., European Patent Application No. 273,202.
- derivatives of ascorbic acid include, but are not limited to, ascorbyl palmitate, magnesium ascorbyl phosphate, sodium ascorbyl phosphate, zinc ascorbyl phosphate, ascorbyl glucoside, sodium ascorbate, and ascorbyl polypeptide.
- An example of a derivative of hydroquinone includes, but is not limited to, arbutin.
- the composition of the present invention further comprises one or more tocopherols and/or tocopherol esters such as tocopherol acetate.
- compositions of the instant invention may be used to great advantage in any of a number of personal/health care products.
- the present compositions may be used in creams, lotions, balms, washes, gels, sticks, sprays, ointments, mousses, and cosmetics/make-up.
- These products may comprise several types of cosmetically-acceptable carrier systems including, but not limited to single phase solutions (e.g., oil based solutions), emulsions, and gels.
- cosmetically-acceptable topical carrier refers to a carrier for topical use that is capable of having the other ingredients dispersed or dissolved therein, and possessing acceptable safety properties.
- the personal care products may be intended for use in skin care, infant care, women's health, wound care, combinations of two or more thereof, and the like, by consumers. Such products may be marketed for any of a variety of benefits including diaper rash reduction, anti-acne, anti-aging, UV protection, soothing, moisturizing, combinations of two or more thereof, and the like.
- the personal/health care products comprising the agent composition of the present invention may further include any of a variety of materials used conventionally in personal care products.
- one or more anionic, nonionic, amphoteric, and/or cationic surfactants, pearlescent or opacifying agents, thickening agents, secondary conditioners, humectants, chelating agents, and additives which enhance the appearance, feel and fragrance of the compositions, such as colorants, fragrances, preservatives, pH adjusting agents, and the like may be used.
- the personal care products produced according to the present invention may comprise any suitable amounts of the present anti-inflammatory compositions.
- the compositions of the present invention have a significant antiinflammatory benefits even when present in personal care formulations in relatively low amounts, for example as low as about 0.02 active weight percent, or less, based on the total weight of the personal care product (herein after the "composition weight percent in product").
- the personal care products of the present invention may comprise from greater than zero to about 5 composition weight percent in product, including from about 0.02 to about 4 composition weight percent in product, from about 0.1 to about 2 composition weight percent in product, and from about 0.1 to about 1 composition weight percent in product.
- the personal care products comprise from greater than zero to about 1 composition weight percent in product, more preferably from about 0.02 to about 0.5 weight percent in product, and even more preferably from about 0.02 to about 0.1 weight percent in product.
- the present invention also provides methods of treating and/or reducing inflammation and/or redness on the skin caused by any of a variety of sources, including, but not limited to, various forms of eczema and psoriasis, acne and rosacea, contact irritant and allergic dermatitis, sunlight-induced dermatoses, infections caused by foreign organisms, insect bites, physical abrasion, and dry skin.
- such methods comprise contacting skin in need of anti-inflammatory treatment with a composition of the present invention described above.
- the present methods comprise contacting the skin with a composition comprising an anti-inflammatory agent selected from the group consisting of olive leaf extract, holly herb, sappan wood, feverfew, and combinations of two or more thereof and an agent comprising at least one lipoaminoacid and at least one metal salt.
- an anti-inflammatory agent selected from the group consisting of olive leaf extract, holly herb, sappan wood, feverfew, and combinations of two or more thereof and an agent comprising at least one lipoaminoacid and at least one metal salt.
- the present invention provides methods of treating and/or reducing inflammation on the skin by contacting skin in need of anti-inflammatory treatment with a personal care product comprising a composition of the present invention.
- compositions and/or personal care products of the present invention may be contacted with skin via any of a variety of means according to the present methods.
- the compositions and products may be applied topically to the skin, hair, or nails.
- the compositions and/or products are applied topically to the skin.
- Mononuclear phagocytes are found in large numbers of the skin and are an important component of the innate immune response.
- macrophages are the primary cells involved in recognizing and eliminating foreign pathogens such as bacteria through production of nitric oxide, a potent pro-inflammatory mediator.
- nitric oxide a potent pro-inflammatory mediator.
- release of nitric oxide can also result in skin inflammation and damage to adjacent skin cells and unregulated nitric oxide production can result in tissue injury.
- the ability of Olive Leaf Extract, Sepicalm or a combination of Olive Leaf Extract and Sepicalm to affect the inflammatory response was illustrated by its ability to reduce macrophage activation in the following assay.
- the murine macrophage cell line (RAW264) cells were adjusted to a density of 4xlO5 6 cells/mL in DMEM with 10% FBS (American Type Culture Collection, Manassas, VA) and 100 ⁇ L was added to a flat-bottomed 96-well tissue culture plate.
- Murine macrophage cells were stimulated with 1 ⁇ g/ml of the bacterial cell well component, lipopolysaccharide (LPS) as positive control or hi the presence or absence of Olive Leaf Extract, Sepicalm or a combination of Olive Leaf Extract and Sepicalm.
- LPS lipopolysaccharide
- Macrophages cultures were treated for 24 hours at 37 0 C with 5% CO 2 in the presence or absence of test samples then Nitrites formation, the stable end product of nitric oxide, were assayed with the Griess assay. Results are expressed as the percent inhibition of inflammatory mediator production compared to a stimulated control culture.
- the ability of Sepicalm to synergistically enhance the anti-inflammatory activity of water soluble and oil soluble extracts of natural materials was illustrated by its ability to reduce macrophage activation in the following assay.
- the murine macrophage cell line (RAW264) cells were adjusted to a density of 4xlO5 6 cells/mL in DMEM with 10% FBS (American Type Culture Collection, Manassas, VA) and 100 ⁇ L was added to a flat-bottomed 96-well tissue culture plate.
- Murine macrophage cells were stimulated with 0.1 ⁇ g/ml of the bacterial cell well component, lipopolysaccharide (LPS) as positive control or in the presence or absence of Sepicalm, water soluble extracts (Siegesbeckia and Lignum Sappan), partially water soluble/ partially oil soluble extracts (Feverfew), oil soluble extracts (Oat Oil Extract, Boswellia Serrata Oil Extract) or a combination of extract plus Sepicalm.
- LPS lipopolysaccharide
- Lignum Sappan also called Sappan Wood, is an aqueous extract of dried heart wood of Caesalpinia sappan. It is used to promote blood circulation and remove blood stasis, and to cause subsidence of swelling and relieve pain.
- Feverfew has both water soluble and oil soluble components. (Indena, Milan Italy). Tanacetum parthenium, a plant commonly known as Feverfew, has been recognized since the Middle Ages as having significant medicinal properties when taken orally — used as a general febrifuge, hence its common name.
- Boswellia Serrata oil extract also called Frankincense is an extract of the oleo-gum resin of the tree, Boswellia serrata, found in the dry forests in parts of India. Its oleo-gum resin is fragrant, transparent and brownish yellow in color.
- the main ingredients of the extract are three triperpene acids, D D, and D-boswellic acids, of which D-boswellic acid has been shown to be responsible for the anti-tumor and anti-arthritic properties of Boswellia serrata.
- Oat oil extract (Dragoco, Totowa, NJ) isolated from oat, Avena sativa, has been used as an anti-irritant and an antioxidant. Macrophage cultures were treated for 24 hours at 37 0 C with 5% CO 2 in the presence or absence of test samples then Nitrites formation, the stable end product of nitric oxide, were assayed for with the Griess assay. Results are expressed as the percent inhibition of inflammatory mediator production compared to a stimulated control culture. RAW 264 Murine Macrophages Stimulated by LPS
- Sepicalm was shown to produce a synergistic increase in anti-inflammatory activity of water soluble extracts (Siegesbeckia and Lignum Sapen), and partially water soluble/ partially oil soluble extracts (Feverfew), but didn't synergistically increase anti-inflammatory activity of oil soluble extracts (Oat Oil Extract, Boswellia Serrata Oil Extract). These findings demonstrate that Sepicalm can potentiate the activity of water soluble extracts and partially water soluble/ partially oil soluble extracts.
- the skin of volunteer subjects was induced to dry out during a conditioning period. Subjects were asked to follow a skin-dry out protocol for 7 days prior to the study. This consisted of washing both legs (from the knee below) with Ivory soap twice a day. This protocol was continued during the course of the study.
- Diffuse reflectance spectroscopy Diffuse reflectance spectroscopy
- the blend of ingredients that have demonstrated a beneficial synergist effect may be incorporated into various types of products.
- the products may include but are not limited to - emulsion, surfactant, anhydrous, tablet/powder, & polymeric systems. Examples of each system type ingredient ranges and the upper and lower limits of the synergistic components are identified as well.
- Emollients/ Skin Conditioners 0.0500 10.0000
- Binder/Caking Agent 0.0000 40.0000
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0520503-4A BRPI0520503A2 (en) | 2005-08-31 | 2005-09-23 | anti-inflammatory compositions and methods of use |
AU2005335943A AU2005335943B2 (en) | 2005-08-31 | 2005-09-23 | Anti-inflammatory compositions and methods of use |
CN2005800518433A CN101291650B (en) | 2005-08-31 | 2005-09-23 | Anti-inflammatory compositions and methods of use |
CA002620429A CA2620429A1 (en) | 2005-08-31 | 2005-09-23 | Anti-inflammatory compositions and methods of use |
EP05801043A EP1933805A4 (en) | 2005-08-31 | 2005-09-23 | Anti-inflammatory compositions and methods of use |
JP2008528998A JP5284093B2 (en) | 2005-08-31 | 2005-09-23 | Anti-inflammatory compositions and methods of use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/216,441 | 2005-08-31 | ||
US11/216,441 US8697152B2 (en) | 2005-08-31 | 2005-08-31 | Anti-inflammatory compositions and personal care compositions comprising olive leaf (Olea europea) extract |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007027187A1 true WO2007027187A1 (en) | 2007-03-08 |
Family
ID=37804508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/034398 WO2007027187A1 (en) | 2005-08-31 | 2005-09-23 | Anti-inflammatory compositions and methods of use |
Country Status (9)
Country | Link |
---|---|
US (1) | US8697152B2 (en) |
EP (1) | EP1933805A4 (en) |
JP (1) | JP5284093B2 (en) |
CN (1) | CN101291650B (en) |
AU (1) | AU2005335943B2 (en) |
BR (1) | BRPI0520503A2 (en) |
CA (1) | CA2620429A1 (en) |
RU (1) | RU2401120C2 (en) |
WO (1) | WO2007027187A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8758838B2 (en) * | 2005-08-31 | 2014-06-24 | Johnson & Johnson Consumer Companies, Inc. | Anti-inflammatory compositions and methods of use |
US8697152B2 (en) | 2005-08-31 | 2014-04-15 | Johnson & Johnson Consumer Companies, Inc. | Anti-inflammatory compositions and personal care compositions comprising olive leaf (Olea europea) extract |
JP5165299B2 (en) * | 2007-07-20 | 2013-03-21 | ポーラ化成工業株式会社 | Topical skin preparation |
US9168207B2 (en) * | 2010-08-19 | 2015-10-27 | Johnson & Johnson Consumer Inc. | Compositions comprising Paulownia tomentosa wood extracts and uses thereof |
CN103415292A (en) * | 2011-01-26 | 2013-11-27 | 阿勒根公司 | Androgen composition for treating an opthalmic condition |
CN106074677B (en) * | 2016-08-05 | 2020-12-22 | 山东大学 | Traditional Chinese medicine composition for preventing and treating skin lesion and aging and application thereof |
BR102016019121A2 (en) * | 2016-08-17 | 2018-03-06 | Natura Cosméticos S.A. | ANTISINAL COSMETIC COMPOSITION, USE OF COMPOSITION, ANTISSINAL TREATMENT METHOD AND METHOD FOR FILLING LIP REGION |
BR102016019120A2 (en) * | 2016-08-17 | 2018-03-06 | Natura Cosméticos S.A. | ANTISINAL COSMETIC COMPOSITION, USE OF THE COMPOSITION, ANTISSINAL TREATMENT METHOD AND WRINKLE REDUCTION METHOD |
CN110709506A (en) * | 2017-07-18 | 2020-01-17 | 株式会社资生堂 | Mesenchymal stem cell guiding agent |
GB202117863D0 (en) * | 2021-12-10 | 2022-01-26 | Givaudan Sa | Cosmetic Ingredient |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6762158B2 (en) * | 1999-07-01 | 2004-07-13 | Johnson & Johnson Consumer Companies, Inc. | Personal care compositions comprising liquid ester mixtures |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2507477A1 (en) | 1981-06-12 | 1982-12-17 | Roussel Uclaf | Antihypertensive extract from olive leaves - contg. oleuropeine, using methanol as extracting solvent |
JPS5823612A (en) | 1981-08-04 | 1983-02-12 | Osaka Chem Lab | Cosmetic composition containing crude drug component |
JPS60260513A (en) * | 1984-06-08 | 1985-12-23 | Lion Corp | Poultice |
SE453724B (en) | 1985-04-18 | 1988-02-29 | Nobel Consumer Goods Ab | Skin care prepn. |
AU618517B2 (en) | 1986-12-23 | 1992-01-02 | Eugene J. Van Scott | Additives enhancing topical actions of therapeutic agents |
US5922701A (en) | 1992-05-01 | 1999-07-13 | University Of Utah Research Foundation | Method for enhancing or accelerating re-epithelialization or re-endothelialization of a tissue |
JPH06172152A (en) | 1992-12-04 | 1994-06-21 | Sunstar Inc | Pimple-preventive cosmetic composition |
JP3769036B2 (en) * | 1994-08-01 | 2006-04-19 | ポーラ化成工業株式会社 | Inhibitor against excessive human body |
JPH09157172A (en) | 1995-12-13 | 1997-06-17 | Lion Corp | Skin external agent and treating agent for eczema |
FR2760362B1 (en) | 1997-03-10 | 2000-08-11 | Vitasterol | COSMETIC OR DERMATOLOGICAL USE OF 7-HYDROXYL STEROIDS |
FR2765109B1 (en) * | 1997-06-25 | 2001-02-09 | Seppic Sa | COMPOSITION COMPRISING A LIPOAMINOACID AND THE CONSTITUENTS OF A TANNIN-RICH PLANT EXTRACT AND USE IN COSMETICS |
IT1298283B1 (en) | 1998-02-19 | 1999-12-20 | B & T S R L | USE OF THE EXTRACT OF EUROPEAN OIL LEAVES AS ANTI-RADICAL |
JPH11343235A (en) * | 1998-04-02 | 1999-12-14 | Ajinomoto Co Inc | Amino acid derivative and inflammation factor activation inhibitor |
JP3929613B2 (en) | 1998-08-20 | 2007-06-13 | 株式会社カネボウ化粧品 | Cosmetics |
EP1010708B1 (en) * | 1998-12-18 | 2004-03-31 | Societe D'exploitation De Produits Pour Les Industries Chimiques, S.E.P.P.I.C. | Use in cosmetics of an inverse latex stable against electrolytes |
JP2000247829A (en) | 1999-02-24 | 2000-09-12 | Mikimoto Pharmaceut Co Ltd | Cosmetic, unregulated drug, medicine and food |
US6440432B1 (en) * | 1999-03-18 | 2002-08-27 | Unilever Home & Personal Care Usa, A Division Of Conopco, Inc. | Skin cosmetic compositions containing dextran or maltodextrin and a weak carboxylic acid |
FR2790977B1 (en) * | 1999-03-19 | 2003-09-12 | Seppic Sa | NEW STABLE WATER-IN-OIL EMULSIONS CONTAINING OLEYL- AND / OR ISOSTEARYL-GLYCOSIDE EMULSIFIER |
GB9908976D0 (en) * | 1999-04-21 | 1999-06-16 | Breed Automotive Tech | A seat belt retractor |
JP2001002550A (en) | 1999-06-18 | 2001-01-09 | Ichimaru Pharcos Co Ltd | Olive leaf extract, application to skin preparation for external use or bathing agent |
FR2808191B1 (en) * | 2000-04-28 | 2004-03-05 | Oreal | PLANT EXTRACT OF THE SPECIES OLEA EUROPAEA AS NO-SYNTHASE INHIBITOR AND USES |
US6440465B1 (en) * | 2000-05-01 | 2002-08-27 | Bioderm, Inc. | Topical composition for the treatment of psoriasis and related skin disorders |
US20050003023A1 (en) * | 2002-06-28 | 2005-01-06 | Meisner Lorraine Faxon | Topical composition for the treatment of psoriasis and related skin disorders |
JP4693012B2 (en) | 2000-06-29 | 2011-06-01 | 一丸ファルコス株式会社 | Phototoxicity inhibitor |
FR2818149A1 (en) | 2000-12-15 | 2002-06-21 | Oreal | COMPOSITION, ESPECIALLY COSMETIC, COMPRISING 7-HYDROXY DHEA AND / OR 7-CETO DHEA AND AT LEAST ONE 5 ALPHA-REDUCTASE INHIBITOR |
US20030077343A1 (en) | 2001-03-16 | 2003-04-24 | Martin Katharine M. | Composition containing feverfew extract and use thereof |
JP4583655B2 (en) | 2001-05-08 | 2010-11-17 | 株式会社ディーエイチシー | Anti-allergic skin external composition |
FR2835252B1 (en) * | 2002-01-25 | 2005-08-05 | Seppic Sa | USE OF A PROTEIN KINASE A INACTIFYING COMPOUND IN A COMPOSITION CONTAINING A COSMETICALLY ACCEPTABLE MEDIUM FOR LAMINATING THE SKIN |
US20030224028A1 (en) * | 2002-05-13 | 2003-12-04 | Societe L'oreal S.A. | Metal complexes for promoting skin desquamation and/or stimulating epidermal renewal |
FR2848116B1 (en) | 2002-12-10 | 2007-01-05 | Nuxe Lab | COSMETIC COMPOSITION COMPRISING A METALLO-PROTEINASE INHIBITOR AND A LIPOPEPTIDE |
FR2851460B1 (en) * | 2003-02-21 | 2007-05-11 | Seppic Sa | USE OF N-LAUROYL AMINOACIDS AS A SLIMMING COSMETIC AND PHARMACEUTICAL ACTIVE |
US20050129759A1 (en) * | 2003-12-16 | 2005-06-16 | Milan Sojka | Sustained release compositions and controlled delivery method |
US20070154532A1 (en) | 2003-12-30 | 2007-07-05 | Med Care S.R.L. | Compositions comprising vitamins and/or derivatives thereof stablished with olea europea extract and/or ionene polymers |
US7691399B2 (en) | 2004-02-03 | 2010-04-06 | Alberto Culver Company | Cosmetic compositions with long lasting skin moisturizing properties |
US20050186269A1 (en) * | 2004-02-25 | 2005-08-25 | Udell Ronald G. | Stabilized feverfew formulations |
US8697152B2 (en) | 2005-08-31 | 2014-04-15 | Johnson & Johnson Consumer Companies, Inc. | Anti-inflammatory compositions and personal care compositions comprising olive leaf (Olea europea) extract |
US8758838B2 (en) * | 2005-08-31 | 2014-06-24 | Johnson & Johnson Consumer Companies, Inc. | Anti-inflammatory compositions and methods of use |
JP4893148B2 (en) * | 2006-08-09 | 2012-03-07 | 株式会社日立製作所 | Shape simplification device and program used therefor |
-
2005
- 2005-08-31 US US11/216,441 patent/US8697152B2/en active Active
- 2005-09-23 RU RU2008112131/15A patent/RU2401120C2/en not_active IP Right Cessation
- 2005-09-23 JP JP2008528998A patent/JP5284093B2/en not_active Expired - Fee Related
- 2005-09-23 AU AU2005335943A patent/AU2005335943B2/en not_active Ceased
- 2005-09-23 BR BRPI0520503-4A patent/BRPI0520503A2/en not_active IP Right Cessation
- 2005-09-23 CN CN2005800518433A patent/CN101291650B/en active Active
- 2005-09-23 EP EP05801043A patent/EP1933805A4/en not_active Withdrawn
- 2005-09-23 CA CA002620429A patent/CA2620429A1/en not_active Abandoned
- 2005-09-23 WO PCT/US2005/034398 patent/WO2007027187A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6762158B2 (en) * | 1999-07-01 | 2004-07-13 | Johnson & Johnson Consumer Companies, Inc. | Personal care compositions comprising liquid ester mixtures |
Also Published As
Publication number | Publication date |
---|---|
BRPI0520503A2 (en) | 2009-05-12 |
US8697152B2 (en) | 2014-04-15 |
RU2008112131A (en) | 2009-10-10 |
JP2009506111A (en) | 2009-02-12 |
EP1933805A4 (en) | 2012-12-26 |
US20070048397A1 (en) | 2007-03-01 |
CN101291650B (en) | 2012-06-27 |
EP1933805A1 (en) | 2008-06-25 |
CN101291650A (en) | 2008-10-22 |
RU2401120C2 (en) | 2010-10-10 |
JP5284093B2 (en) | 2013-09-11 |
CA2620429A1 (en) | 2007-03-08 |
AU2005335943A1 (en) | 2007-03-08 |
AU2005335943B2 (en) | 2012-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2620763C (en) | Anti-inflammatory compositions and methods of use | |
US8697152B2 (en) | Anti-inflammatory compositions and personal care compositions comprising olive leaf (Olea europea) extract | |
JP7054242B2 (en) | Hair papilla cell activation promoter and VEGF production promoter | |
ES2289532T3 (en) | EMPLOYMENT OF DIFENYLMETHANE DERIVATIVES AS INHIBITORS OF TIROSINASA. | |
CN110035797B (en) | Synergistic herbal composition with prebiotic properties for the treatment of acne | |
US20070116696A1 (en) | Lotus and methyl donors | |
JP2022546928A (en) | TOPICAL FORMULATIONS CONTAINING CANNABIDIOL, METHODS FOR PREPARATION OF COMPOSITIONS AND USES THEREOF | |
TW201417822A (en) | Topical compositions for the treatment of acne | |
CA2309179A1 (en) | Method and composition for reducing dermatological aging and for reduci ng bruising | |
EP2691090A2 (en) | Tight junctions modulators | |
JP6255154B2 (en) | Topical skin preparation | |
JP2015189735A (en) | expression inducer of heat shock protein | |
KR20140118321A (en) | Composition for treating skin disease comprising sulfur, alum and vinegar | |
JP2009046428A (en) | Elastase inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200580051843.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2620429 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008528998 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005335943 Country of ref document: AU |
|
REEP | Request for entry into the european phase |
Ref document number: 2005801043 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005801043 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008112131 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2005335943 Country of ref document: AU Date of ref document: 20050923 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: PI0520503 Country of ref document: BR Kind code of ref document: A2 |